July 13, 2016 / 12:02 PM / a year ago

BRIEF-Nuvo Pharmaceuticals- Pennsaid trial to support regulatory approvals in E.U., Canada And Australia

1 Min Read

July 13 (Reuters) - Nuvo Pharmaceuticals Inc

* Topline results of trial are expected to be available in late Q2 or early Q3 2017

* Nuvo Pharmaceuticals Inc announces Pennsaid 2% phase 3 trial to support regulatory approvals in the E.U., Canada and Australia

* Nuvo Pharmaceuticals Inc says trial will cost approximately cdn$1.5 million spread over second half of 2016 and first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below